PlaCCine:一种功能性聚合物配制的COVID-19 DNA疫苗在小鼠中诱导强免疫原性和保护作用
PlaCCine是一种依赖合成DNA递送系统、不依赖病毒或设备的DNA疫苗平台,其功能化聚合物与DNA结合后在4℃可稳定12个月、25℃可稳定1个月。小鼠肌肉注射表达D614G、Delta或D614G+Delta刺突蛋白的DNA疫苗(pVAC15、pVAC16、pVAC17)后,诱导了刺突特异性体液和细胞免疫应答,免疫应答维持至接种后14个月;在K18 hACE2转基因小鼠攻毒研究中,肺病毒载量降低超过90%并改善临床评分。
要点
- PlaCCine功能化聚合物-DNA复合物在4℃稳定12个月、25℃稳定1个月。
- 小鼠肌肉注射pVAC15、pVAC16或pVAC17后诱导刺突特异性抗体和T细胞应答。
- K18 hACE2转基因小鼠攻毒后肺病毒载量降低超过90%并改善临床评分。
核心结论
- PlaCCine DNA疫苗有效且稳定,值得针对新出现的SARS-CoV-2变异株进一步开发。
研究设计与样本
- 研究为小鼠免疫原性研究和K18 hACE2转基因小鼠免疫与攻毒研究,评估表达D614G(pVAC15)、Delta(pVAC16)或D614G+Delta组合(pVAC17)刺突蛋白的DNA疫苗。
主要发现
- PlaCCine功能化聚合物与DNA结合后在4℃稳定12个月、25℃稳定1个月。
- 与裸DNA相比,功能化聚合物-DNA在小鼠骨骼肌中的转染效率提高5-15倍。
- 小鼠肌肉注射pVAC15、pVAC16或pVAC17后,一次免疫即可观察到抗体应答,第二次注射两周后终点IgG滴度增至大于1×10^5。
- 假病毒竞争试验检测到pVAC15、pVAC16或pVAC17接种后的中和抗体,流式细胞术显示细胞免疫应答包括CD4和CD8刺突特异性T细胞。
- 接种小鼠的免疫应答维持至接种后14个月;K18 hACE2转基因小鼠攻毒研究中,pVAC15、pVAC16和pVAC17诱导的免疫应答使肺病毒载量降低超过90%并改善临床评分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DNA- based vaccines have demonstrated the potential as a safe and effective modality. PlaCCine, a DNA-based vaccine approach described subsequently relies on a synthetic DNA delivery system and is independent of virus or device. The synthetic functionalized polymer combined with DNA demonstrated stability over 12 months at 4C and for one month at 25C. Transfection efficiency compared to naked DNA increased by 5-15-fold in murine skeletal muscle. Studies of DNA vaccines expressing spike proteins from variants D614G (pVAC15), Delta (pVAC16), or a D614G + Delta combination (pVAC17) were conducted. Mice immunized intramuscular injection (IM) with pVAC15, pVAC16 or pVAC17 formulated with functionalized polymer and adjuvant resulted in induction of spike-specific humoral and cellular responses. Antibody responses were observed after one immunization. And endpoint IgG titers increased to greater than 1x 105 two weeks after the second injection. Neutralizing antibodies as determined by a pseudovirus competition assay were observed following vaccination with pVAC15, pVAC16 or pVAC17. Spike specific T cell immune responses were also observed following vaccination and flow cytometry analysis demonstrated the cellular immune responses included both CD4 and CD8 spike specific T cells. The immune responses in vaccinated mice were maintained for up to 14 months after vaccination. In an immunization and challenge study of K18 hACE2 transgenic mice pVAC15, pVAC16 and pVAC17 induced immune responses lead to decreased lung viral loads by greater than 90 % along with improved clinical score. These findings suggest that PlaCCine DNA vaccines are effective and stable and further development against emerging SARS-CoV-2 variants is warranted.
引用
- Sood S, Matar MM, Kim J, et al. Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer. Vaccine. 2024. PMID: 38302336. doi:10.1016/j.vaccine.2024.01.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。